251 related articles for article (PubMed ID: 33040178)
1. Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid.
Volpato M; Ingram N; Perry SL; Spencer J; Race AD; Marshall C; Hutchinson JM; Nicolaou A; Loadman PM; Coletta PL; Hull MA
Cancer Chemother Pharmacol; 2021 Feb; 87(2):173-184. PubMed ID: 33040178
[TBL] [Abstract][Full Text] [Related]
2. The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility.
Hawcroft G; Volpato M; Marston G; Ingram N; Perry SL; Cockbain AJ; Race AD; Munarini A; Belluzzi A; Loadman PM; Coletta PL; Hull MA
Br J Pharmacol; 2012 Jul; 166(5):1724-37. PubMed ID: 22300262
[TBL] [Abstract][Full Text] [Related]
3. COX-2 inhibition and colorectal cancer.
Koehne CH; Dubois RN
Semin Oncol; 2004 Apr; 31(2 Suppl 7):12-21. PubMed ID: 15252926
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of COX-2 in colon cancer modulates tumor growth and MDR-1 expression to enhance tumor regression in therapy-refractory cancers in vivo.
Rahman M; Selvarajan K; Hasan MR; Chan AP; Jin C; Kim J; Chan SK; Le ND; Kim YB; Tai IT
Neoplasia; 2012 Jul; 14(7):624-33. PubMed ID: 22904679
[TBL] [Abstract][Full Text] [Related]
6. A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate.
Crew TE; Elder DJ; Paraskeva C
Carcinogenesis; 2000 Jan; 21(1):69-77. PubMed ID: 10607736
[TBL] [Abstract][Full Text] [Related]
7. c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells.
Lin YM; Lu CC; Hsiang YP; Pi SC; Chen CI; Cheng KC; Pan HL; Chien PH; Chen YJ
J Cell Physiol; 2019 Jul; 234(7):10336-10344. PubMed ID: 30480806
[TBL] [Abstract][Full Text] [Related]
8. Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells.
Hawcroft G; Loadman PM; Belluzzi A; Hull MA
Neoplasia; 2010 Aug; 12(8):618-27. PubMed ID: 20689756
[TBL] [Abstract][Full Text] [Related]
9. Novel Molecular Mechanism of Aspirin and Celecoxib Targeting Mammalian Neuraminidase-1 Impedes Epidermal Growth Factor Receptor Signaling Axis and Induces Apoptosis in Pancreatic Cancer Cells.
Qorri B; Harless W; Szewczuk MR
Drug Des Devel Ther; 2020; 14():4149-4167. PubMed ID: 33116404
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase/lipoxygenase shunting lowers the anti-cancer effect of cyclooxygenase-2 inhibition in colorectal cancer cells.
Ganesh R; Marks DJ; Sales K; Winslet MC; Seifalian AM
World J Surg Oncol; 2012 Sep; 10():200. PubMed ID: 23013454
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells.
Qin J; Yuan J; Li L; Liu H; Qin R; Qin W; Chen B; Wang H; Wu K
Biomed Pharmacother; 2009 Mar; 63(3):241-8. PubMed ID: 18617357
[TBL] [Abstract][Full Text] [Related]
13. Whole-Body PET Imaging in Humans Shows That
Kim MJ; Anaya FJ; Manly LS; Lee JH; Hong J; Shrestha S; Telu S; Henry K; Santamaria JAM; Liow JS; Zanotti-Fregonara P; Shetty HU; Zoghbi SS; Pike VW; Innis RB
J Nucl Med; 2023 Jan; 64(1):159-164. PubMed ID: 35798558
[TBL] [Abstract][Full Text] [Related]
14. Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
Zhang Z; Ghosh A; Connolly PJ; King P; Wilde T; Wang J; Dong Y; Li X; Liao D; Chen H; Tian G; Suarez J; Bonnette WG; Pande V; Diloreto KA; Shi Y; Patel S; Pietrak B; Szewczuk L; Sensenhauser C; Dallas S; Edwards JP; Bachman KE; Evans DC
J Med Chem; 2021 Aug; 64(15):11570-11596. PubMed ID: 34279934
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic low-dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis.
Rohwer N; Kühl AA; Ostermann AI; Hartung NM; Schebb NH; Zopf D; McDonald FM; Weylandt KH
Cancer Med; 2020 Apr; 9(7):2535-2550. PubMed ID: 31994315
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer.
Schrör K
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):473-84. PubMed ID: 22122764
[TBL] [Abstract][Full Text] [Related]
17. Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
Yao M; Zhou W; Sangha S; Albert A; Chang AJ; Liu TC; Wolfe MM
Clin Cancer Res; 2005 Feb; 11(4):1618-28. PubMed ID: 15746067
[TBL] [Abstract][Full Text] [Related]
18. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1.
Rimon G; Sidhu RS; Lauver DA; Lee JY; Sharma NP; Yuan C; Frieler RA; Trievel RC; Lucchesi BR; Smith WL
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):28-33. PubMed ID: 19955429
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
[TBL] [Abstract][Full Text] [Related]
20. [The growth inhibitory effect of non-steroid anti-inflammatory drugs on ovarian cancer].
Wang HJ; Peng ZL; Liu XQ; Yang KX; Lou JY; Luo FM
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 38(3):428-32. PubMed ID: 17593823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
